Binu John

Breaking news:@JAMAInternalMed #COVIDVaccination ->delayed in #cirrhosis but works against severe disease! ☝️One dose -> 64.8% ↓ #COVID19 ✌️Two doses ->78.6%↓ COVID19 #livertwitter #medtwitter #GITwitter @MiamiVAMC @VCUHealth @VCU @UMiamiMedNews jamanetwork.com/journals/jamai…

Best practices for managing ascites, volume overload & hyponatremia in cirrhosis. Our new CPU in @AGA_Gastro shares 1️⃣3️⃣ evidence-based tips to support clinical decision-making. Read more here: ow.ly/4zLY50XLcfX @orman_md @BrettEFortuneMD @AsraniSumeet #GITwitter

@AmerGastroAssn @AGA_Gastro @orman_md @BrettEFortuneMD @AsraniSumeet Thank you for sharing. Proud to be part of this effort with an all-star cast of @BrettEFortuneMD from @univmiami and @orman_md @indiana @IndianaUniv who are co- first authors and @asraniSummet from @Baylor Dallas

🔥Metylated blood-based HCC biomarker is more sensitive than US for #HCC surveillance. #TLM25 by @docbinujohn @AASLDtweets @DrHuangDQ @Apichatka @wonglaihung

@pgholam One the unique things in our field that we have treatments to offer for almost every condition we manage. From MASH to viral hepatitis to PBC,HCC, portal hypertension and decompensated cirrhosis. PSC and some rare exceptions. Super rewarding! Very few specialties can say that 😊

Every time a trainee tells me they are considering going into #hepatology my heart goes aflutter! Hepatology is a fulfilling & rewarding specialty. It has a huge manpower problem. An estimated 15 Mil Americans have serious liver dz and 100 Mil have #MASLD ! #livertwitter

🚨 New insights on managing hepatitis delta virus (HDV): Our new CPU, published in @AGA_Gastro, highlights screening, diagnosis, and therapies. 📖 Read more: ow.ly/wOuS50X6oYO @TatyanaKushner @Robert_J_Wong #GItwitter

Today was a full day with our #AGAleaders! Plenty of conversation to chart a path forward for AGA and the future of GI. 🙌🏼 @docbinujohn @LarryKimMD @DrLorenGR @MccutchenDr @MichelleKimMD @ShaziaMSiddique @JHashashMD @IBDimmunology

@pgholam 😂😆

What do violence and ceruloplasmin have in common? They are both never the answer. #livertwitter

@pgholam @docamitgs @AASLDtweets Thank you @pgholam @docamitgs is a co-author and a key contributor on the paper 😊

Great work by @docbinujohn et al. I’m sure @docamitgs and the @AASLDtweets guidelines committee are weighing this and other studies with similar results in the next iteration of the @AASLDtweets #HCC guidelines #livertwitter

MASLD-HCC can occur in absence of cirrhosis Our study 30,414 patients with MASLD in Hepatology HCC risk ↑ by 18% per 5kPa ↑ in LSM In pts with MASLD without cirrhosis, LSM of ≥10 kPa and diabetes, HCC risk is high enough to warrant screening lnkd.in/e5fHZHZ8

@RayRamMD Thank you 🙏

concerning development in #MASLD resesech! this could be practice changing #livertwitter

@JonathanStineMD @AstraZeneca Congratulations 🎈🍾🎉🎊- @JonathanStineMD Good luck on your your next chapter!

After 8 yrs in academic medicine, I'm absolutely delighted to announce I’ve joined @AstraZeneca as a Global Clinical Lead. Starting today, I hope to advance innovative therapies for liver & metabolic diseases alongside an incredible team. Onward to this new chapter! #MASLD #MASH

@renumathyd @NatRevGastroHep Wow- amazing! congratulations 🎊🎈🍾🎉

@KavishPatidar11 Congratulations- nice work! 🎈🎊🎉

How common is ambulatory AKI (AKI occurring in an outpatient setting) in cirrhosis? ✅It’s common➡️1 in 8 ✅Underrecognized➡️42% ✅Key precipitants➡️hypovolemia 2/2 diuretics & GI losses, & nephrotoxin medication exposure ✅Deadly➡️1 in 8 ☠️at 90d 🔥🔥cghjournal.org/article/S1542-…

@JonathanStineMD Congratulations 🍾🎈🎉🎊

Over the 🌑 to find out today that I have been promoted to Full Professor! So grateful for every mentor, collaborator, trainee, friend and especially my family who have helped me along the way. I am so excited to keep pushing forward in research, clinical care, and education.

We need to spread the word about MASH Awareness is low, particularly amongst people at risk and frontline providers Hot of the presses in @HepCommJournal journals.lww.com/hepcomm/fullte… #easl2025

@AlkhouriNaim @DDWMeeting @atreja @binuj @MadrigalPharma @Pinnacle_TX @geneyim @novonordisk @NorthshoreGI @NoureddinMD Great seeing co-GI and hepatology fellows from training @AlkhouriNaim @atreja @CCF_GIFellows

It was great seeing some old colleagues at @DDWMeeting . All doing exceptionally great things. Also nice to see all the new drugs for liver diseases making an impact:) @atreja @binuj @MadrigalPharma @Pinnacle_TX @geneyim @novonordisk @NorthshoreGI @NoureddinMD

@MattiasMandorf1 Nice to see someone with a sense of humor 😀

Conversation with the Customs employee at the airport when entering the U.S. for a 1-day meeting: When is your flight back? - Tomorrow. - So they pay you well. - No, I'm in academia. - Oh, so they own you. 😋

Grateful for the invitation to speak @cddw_clm on "Remote evaluation of liver transplantation" in beautiful Quebec with some great speakers from @UofT . @CynthiaTsien @NaziaSelzner

@geneyim @ColumbiaMed @NYC_Tx_Hep Congratulations @geneyim 🎈🎊🎉 Good luck 🍀 on your new role!

I'm thrilled to announce that I have joined @ColumbiaMed @NYC_Tx_Hep as the Director of the Advanced Interdisciplinary Alcohol Liver Program and Treatment (ADAPT), a patient-centered, integrated care and research program for patients with alcohol-associated liver disease (ALD).